Clinical Trials

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT02755272 2025-07-04

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

87 enrolled

BreastGastrointestinalGynecologicSarcoma

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02632448 2025-05-02

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

Phase 1/2 Completed

229 enrolled

Breast Neoplasms, Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Recurrence, Sarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Triple Negative Breast Neoplasms

NCT03997968 2024-12-24

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Phase 1/2 Completed

169 enrolled

BreastGastrointestinalGynecologicHead & NeckLymphoidPlasma cellSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Lymphoma, Mantle-Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02819518 2024-11-27

KEYNOTE-355

882 enrolled 41 charts 2 FDA

BreastGastrointestinalThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT03267316 2024-08-22

CANFOUR

Phase 1/2 Completed

167 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04799249 2024-08-01

PRESERVE 2

194 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04464174 2024-07-26

PATHFINDER

Phase 2 Completed

54 enrolled

Triple Negative Breast Neoplasms

NCT02996825 2024-04-02

Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

44 enrolled

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04739670 2024-03-01

BELLA

31 enrolled

Phase 2/3 Active not recruiting

Recurrence, Triple Negative Breast Neoplasms

NCT02641847 2024-01-25

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

503 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05809895 2023-07-24

AdvanTIG-211

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT03567720 2023-06-01

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

65 enrolled

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03002103 2023-04-26

A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer

Phase 3 Suspended

420 enrolled

BreastGastrointestinalGenitourinaryHead & NeckThoracic

Triple Negative Breast Neoplasms

NCT04060342 2022-08-18

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Phase 1 Terminated

61 enrolled

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03674242 2022-08-01

Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2)

Phase 2/3 Terminated

27 enrolled

Triple Negative Breast Neoplasms

NCT04297267 2022-07-22

nonpCR GP

100 enrolled

Triple Negative Breast Neoplasms

NCT03102320 2022-06-30

ARCS-Multi

BreastGastrointestinalThoracic

173 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms, Pancreatic Neoplasms, Thymoma, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT02546934 2022-04-22

TNBC

254 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02341911 2022-04-20

TNBC

150 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04745975 2022-04-20

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

100 enrolled

Triple Negative Breast Neoplasms

NCT02978716 2022-03-23

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)

Phase 2 Terminated

102 enrolled 51 charts

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT02555657 2021-12-10

KEYNOTE-119

622 enrolled 26 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

BreastGastrointestinalGynecologicHead & NeckThoracic

32 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04517292 2020-08-18

GEP

160 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02309177 2019-05-31

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

BreastGastrointestinalThoracic

114 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT01881230 2019-02-21

tnAcity

Phase 2/3 Completed

191 enrolled 22 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01939418 2017-10-03

Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer

Phase 1/2 Terminated

23 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00813956 2016-03-17

A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer

Phase 2 Completed

80 enrolled

Triple Negative Breast Neoplasms

NCT01287624 2015-03-23

TNBC

240 enrolled